| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
SQOR[1]
|
|---|---|
| ln Vitro |
FC9402 reduces left ventricular (LV) fibrosis and cardiomyocyte hypertrophy brought on by TAC[1]. In vitro studies have shown that FC9402 effectively attenuates pressure overload-induced cardiomyocyte hypertrophy by inhibiting SQOR activity. Experimental data indicate that this compound has a direct regulatory effect on alleviating the pathophysiological growth response of cardiomyocytes .
|
| ln Vivo |
FC9402 has also demonstrated positive therapeutic effects in in vivo animal models. Research confirms that this compound significantly reduces left ventricle (LV) fibrosis induced by transverse aortic constriction (TAC) and improves cardiac function. These results suggest the potential value of FC9402 in intervening in pathological cardiac remodeling .
|
| References |
[1]. WO 2020/146636 A1
|
| Additional Infomation |
FC9402 (FC-9402) is a potent and selective small-molecule inhibitor of sulfide quinone oxidoreductase (SQOR), with the molecular formula C19H16N4O and a molecular weight of 316.36 . This compound exhibits significant activity in cardiovascular regulation and is primarily used to study the therapeutic mechanisms of cardiomyocyte hypertrophy and cardiac fibrosis .
|
| Molecular Formula |
C19H16N4O
|
|---|---|
| Molecular Weight |
316.4
|
| Exact Mass |
316.132
|
| CAS # |
2452401-65-7
|
| PubChem CID |
154644670
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
2.8
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
24
|
| Complexity |
454
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1(C2=NC=CC=C2C)=NC(OC)=C(C#N)C(C2=CC=C(N)C=C2)=C1
|
| InChi Key |
FSYJNCHUENWJEE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H16N4O/c1-12-4-3-9-22-18(12)17-10-15(13-5-7-14(21)8-6-13)16(11-20)19(23-17)24-2/h3-10H,21H2,1-2H3
|
| Chemical Name |
4-(4-aminophenyl)-2-methoxy-6-(3-methylpyridin-2-yl)pyridine-3-carbonitrile
|
| Synonyms |
FC9402; FC 9402; 2452401-65-7; FC-9402; CHEMBL5088404; orb1689207; SCHEMBL22208263;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (316.10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1606 mL | 15.8028 mL | 31.6056 mL | |
| 5 mM | 0.6321 mL | 3.1606 mL | 6.3211 mL | |
| 10 mM | 0.3161 mL | 1.5803 mL | 3.1606 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA